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Abstract
Diabetic retinopathy (DR) is a devastating sight-threatening complication of diabetes mel-
litus (DM). Besides damaging the vascular system of the retina, DM will also destruct 
the tissue surrounding the retina, including the optic nerve. DR impairs the optic nerve 
by damaging its conduction and integrity. There are few clinical manifestations of optic 
nerve changes in DR such as diabetic papillopathy, neovascularization of optic disc, and 
optic nerve atrophy. These involve metabolic alterations related to DM, production of 
advanced glycation end products (AGEs), oxidative stress, and hemodynamic changes. 
Diagnostic tests including visual evoked potential (VEP) and optical coherence tomog-
raphy (OCT) can detect functional and structural changes. This finding is important as it 
may reflect the early loss of retinal ganglion cell axons. As the neuronal loss is irreversible, 
it is pivotal to be able to screen these nervous system changes in the early stage of DR and 
prevent further deterioration.
Keywords: diabetes mellitus, diabetic papillopathy, diabetic retinopathy, 
neovascularization of optic disc, optical coherence tomography, optic nerve,  
optic atrophy, visual evoked potential
1. Introduction
Diabetic retinopathy (DR), a devastating sight-threatening complication of diabetes mellitus 
(DM), is one of the most prevalent health diseases worldwide with an incidence of 6.9% [1–3]. 
The number of people with diabetes is estimated to rise from 171 million in 2000 to 366 million 
in 2030. A study by Jin et al. in DM type 2 population showed that within 5 years, the cumula-
tive incidence of DR was 46.9% with 13.9% population suffering from severe nonproliferative 
DR (NPDR) and 4.6% from proliferative DR (PDR). Hence, more people will be at risk of 
developing DR and in danger of losing their sight [4, 5].
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DM endangers sight by damaging the neurovascular system of the eye, including the optic 
nerve [6, 7]. The damages include changes in angioarchitecture, blood flow and degenerative 
loss of neural tissue, morphological changes, changed protein expression, and changed neuro-
transmission and neurotransmitters [6–9]. Recently, not so many studies have been conducted 
to elucidate damage due to DM and DR in the optic nerve and central visual pathway. We 
hypothesize that optic nerve damage occurs due to few processes in DM. Such processes are 
metabolic alteration, oxidative stress, and ischemia [10]. These changes could be detected via 
modalities such as visual evoked potential, biomicroscopy, and fundus photography [11–13]. 
These changes usually occur after persistent metabolic alterations, which may lead to late detec-
tion [2, 14]. Therefore, early detection of optic nerve involvement in DR may be beneficial to 
provide timely recognition and management for patients at greater risk of DR progression [14].
2. Pathophysiology
There are few processes in DR affecting the optic nerve. Such processes are metabolic altera-
tions related to DM, production of advanced glycation end products (AGEs), oxidative stress, 
and hemodynamic changes. These processes will be discussed in detail below.
2.1. Metabolic alterations
Findings from animal studies suggest that neurodegeneration in DR is caused by both dimin-
ished insulin receptor signaling and systemic hyperglycemia [15–17]. Insulin plays an important 
role, as insulin receptors in the retina stimulate neuronal development, growth, and anabolic 
synthesis [18, 19]. Therefore, a defect in insulin function either due to a low level of insulin or 
impaired sensitivity would hamper neuroretinal cells’ survival. As diabetes progresses, retinal 
neurons start to degenerate by apoptosis within weeks after the onset [20, 21]. Metabolic altera-
tion and hormonal factors might affect balance of some mediators including growth factors, 
cytokines, inflammatory, and adhesion molecules [22]. These alterations result in abnormal 
capillary permeability, apoptosis of capillary cells, and angiogenesis [23].
Metabolic alteration also damages neural conduction in the postretinal central visual pathway 
[10]. A recent study in diabetic rats showed that there is reduction of Na+/K+/ATPase enzyme 
in the optic nerve [24]. This enzyme is important for maintaining sodium potassium gradient 
within cells and controls the membrane axon depolarization/repolarization. When impaired, 
it suggests that the neuronal conduction and integrity are damaged.
2.2. Advanced glycation end products
Hyperglycemia induces reaction of sugar and protein via Maillard reaction and produces 
advanced glycation end products (AGEs) [25, 26]. AGEs play a huge role in complications of 
DM as it triggers further oxidative stress and vascular cross-linking and activates pro-inflam-
matory cytokines [20, 21]. Neriyanuri et al. reported that AGEs were independent predictors 
of development of DR in addition to blood glucose and glycated hemoglobin [14].
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AGEs are long-lasting, irreversible products that can modify blood vessel elasticity [25]. High-
level AGEs in the optic disc affect elasticity of lamina cribrosa. As the intraocular pressure 
increases, cribriform plates become unable to bear the strain. This condition may develop into 
glaucoma in DR [27].
2.3. Oxidative stress
Hyperglycemia stimulates increased flux through the glycolytic and tricarboxylic acid cycle 
pathways, hence resulting in excessive electrons within mitochondria [28]. These electrons 
would react with oxygen and form reactive oxygen species (ROS). Since mitochondria as cells’ 
powerhouse also generate ROS on their own, they are also the first ones to be damaged by 
increased ROS. This results in reduced mitochondrial energy production, later causing loss of 
cellular and tissue function [29].
Oxidative stress also contributes to neural retinal ganglion cell and optic nerve injury through 
the impairment of L-glutamate/L-aspartate transporter (GLAST), which increases extracel-
lular accumulation of glutamate and promotes excitotoxicity [30–32]. Glutamate is a neu-
rotransmitter that plays a role in the regulation of neurohormonal activity and is found in high 
levels in the central nervous system. Upon stimulation of nerve cells, glutamate molecules are 
released from the glutamatergic synaptic vesicles and cause depolarization of the postsynap-
tic neuronal membrane, which generates signal. Accumulated glutamate in the synaptic space 
is then collected by adjacent astrocytes, afterward being broken down into glutamine [21].
In patients with DR, glutamate accumulates in extracellular space due to the following mecha-
nisms: (1) reduction of Müller cell–specific enzyme glutamine synthetase, which converts glu-
tamate to glutamine; (2) decrease in the retinal ability to oxidize glutamate to α-ketoglutarate; 
and (3) impairment of glutamate uptake by the glial cells [29]. The accumulation of gluta-
mate results in overactivity of ionotropic glutamate receptors, such as α-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA) and N-methyl-D-aspartate (NMDA) receptors, 
which later causes uncontrolled intracellular calcium response in postsynaptic neurons and 
eventually cell death [33, 34]. Recent studies suggest that glutamate excitotoxicity results in 
apoptotic degenerative lesions [25]. Glutamate toxicity also causes depletion of glutathione, 
which is an antioxidant, thus contributing to oxidative stress [35].
A recent study in diabetic rats also showed marked increase in oxidative stress level shown 
by malondialdehyde (MDA) level in the optic nerve and visual cortex. In addition, they also 
found reduced antioxidant, glutathione (GSH), in both the optic nerve and visual cortex [24]. 
These results suggest significant oxidative stress in the optic nerve and visual cortex along 
with impairment in neuronal conduction and integrity. Other studies have also found simi-
lar result, showing impaired retrograde and anterograde axonal transport in the optic nerve 
of diabetic rats along with retinal ganglion cell axonopathy [36, 37]. A study by Sokol et al. 
showed that when induced with ischemia, myelinated axons degenerated and became dis-
ordered [38]. Further changes are swollen and collapsed axons, and by 90th minute, myelin 
sheaths were fragmented. Joachim et al. found axonal damage and gliosis of the optic nerve 
after ocular ischemia. Renner et al. found damaged optic nerve in an ischemic rat model. 
Histologic examination revealed demyelination and subsequent loss of myelin sheaths after 
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ischemia [39]. In addition, they also found marked microglia activation, upregulation of astro-
cytes, reduction of myelin basic protein and myelin oligodendrocyte glycoprotein (MOG), 
as well as the reduction in oligodendrocytes [40]. The optic nerve structure was also affected 
as neurofilament was found to be distorted after 21 days of ischemia/reperfusion induction. 
Ischemia also seemed to impair neuronal immune system as the study found destroyed astro-
glia structure, hence leaving the nerve tissue susceptible to insults, i.e., oxidative stress [40].
2.4. Hemodynamic changes
Chronic hyperglycemia damages the retinal blood vessels and causes pericyte loss due to 
elevated sorbitol level. These result in involution of the vascular changes in microcirculation 
and loss of normal capillary exchange [12–14]. Microvascular anomalies and chronic inflam-
mation may develop dysfunctional barriers permitting leakage of inflammatory molecules and 
immune cells from systemic circulation and cause further deterioration of the tissue [12, 41].
Another process that plays a major part in DR is capillary degeneration due to weakness 
and dilation of capillary walls’ saccular outpouching, commonly known as microaneurysms. 
Rupture of these microaneurysms leads to leakage of endovascular products, including blood 
[9]. In DR, blood viscosity was significantly higher, thus resulting in reductions in blood flow. 
Persistent uncorrected blood flow causes chronic mild hypoperfusion, which might lead to 
ischemia and a rise in waste products [42, 43].
Accumulation of these molecules and cells leads to retinal occlusion, which later progresses 
into hypoxia [44]. Hypoxia results in upregulation of vascular endothelial growth factor (VEGF) 
platelet adhesiveness, erythrocyte aggregation, serum lipids, and fibrinolysis [45, 46]. VEGF 
promotes new blood vessel growth resulting in abnormal neovascularization [47].
3. Clinical manifestation
There are few clinical manifestations of optic nerve damage related to DM and DR that can be 
observed. Those are diabetic papillopathy, neovascularization of optic disc, and optic nerve 
atrophy [48]. Those will be discussed further below.
3.1. Diabetic papillopathy
3.1.1. Definition
Diabetic papillopathy (DP) is an ocular manifestation of both type 1 and type 2 DM character-
ized by unilateral or bilateral hyperemic disc swelling with minimal or no optic nerve dysfunc-
tion, which generally resolves without medical intervention [49, 50]. Patients with DP are often 
asymptomatic, but may sometimes experience transient decrease in visual acuity [50]. It is 
usually self-limiting and tends to resolve over a period of 2–10 months with the average time 
of 3.7 months, leaving minimal sequelae [51, 52]. Visual acuity generally recovers to better than 
20/30 in most patients [53].
Optic Nerve88
DP typically affects young people with type 1 DM, but it has also been reported to occur in 
elderly patients with type 2 DM. The prevalence of DP in both types of DM is 0.5% and the 
percentage of DP patients presenting with nonproliferative diabetic retinopathy (NPDR) is 
higher than in the proliferative diabetic retinopathy (PDR) [49].
3.1.2. Pathophysiology
The pathophysiology of diabetic papillopathy remains poorly understood and several theories 
have been suggested [49]. Some researchers suggest that DP is a subtype of anterior ischemic 
optic neuropathy (AION), but there are different features between DP and AION that others 
argue that it is a completely different pathological process [49, 50]. For instance, DP is an asymp-
tomatic optic disc edema, whereas AION is an acute optic disc infarction [54, 55]. Researchers 
support the argument that the pathophysiology of DP is distinguishable from AION [50]. A 
study evaluating fluroangiographic aspects by Brancato et al. showed robust leakage of fluo-
rescein, suggesting that DP is a local nonhypotensive vasculopathy [56]. These findings are 
supported by Bayraktar et al. and Regillo et al., who showed notable telangiectatic vasculature 
and fluroangiographic hyperfluorescence [54, 57]. Meanwhile, case studies of AION by Hayreh 
et al. and Shin et al. demonstrated notable filling defects in fluroangiography [55, 58]. These 
findings of AION contrast with the hyperfluorescence that has been noted in cases of DP.
In patients with DP, the degree of DR tends to be mild. Regillo et al. observed that DP might 
be a separate entity rather than extension of DR [57]. Otherwise, a case series by Ostri et al. 
reported that three out of four patients with DP who already had DR before proceeded to 
develop high-risk PDR. This condition is called “early worsening phenomenon of DR “ where 
progression of retinopathy and papillopathy was accelerated, while adaptation was remark-
ably slow in the very first year [59]. Bayraktar et al. also reported two cases of nonproliferative 
diabetic retinopathy (NPDR), which later on were also diagnosed as having DP. A 3-month 
follow-up showed that retinopathy worsened and developed into proliferative diabetic 
retinopathy (PDR) [54]. Lubow et al. found that two of three patients with DP subsequently 
developed PDR and vitreous hemorrhage [60]. Hayreh et al. reported similar findings and 
observed three patients with DP, who later on were also diagnosed as having PDR [55]. 
Hence, DP should be considered as a risk factor for progression to PDR and patients should 
be observed closely taking into account this possibility [54].
Early DP study by Appen et al. hypothesized that DP patients sustain a local vasculopathy 
of the optic disc, presumably in relation to diabetes [61]. This vasculopathy induces transient 
leakage of fluid, which results in disc edema. The authors also suggest that the presence of 
edema causes axoplasmic flow turmoil. An earlier study by Freund et al. showed that pro-
longed hyperglycemia and anoxia due to the failure of glucose utilization cause damages to the 
optic nerve [62]. Recent study by Slagle et al. suggested that clinically visible interstitial edema 
of the optic nerve head due to vascular hyperpermeability initiates the pathology of DP [50].
Slagle et al. elucidate that tissue perfusion depends on two main factors: (1) the ability of the 
blood to reach the tissue through patent vessels and (2) the dispersion of nutrients to the tissue 
via fluid movement through the capillary bed. There are four primary forces that determine per-
fusion: (1) capillary pressure, (2) interstitial fluid pressure, (3) plasma colloid osmotic pressure, 
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and (4) interstitial fluid colloid osmotic pressure [50]. The authors hypothesized that impair-
ment in the transportation and reabsorption of fluid through the capillary walls causes capillary 
vasostatic perfusion pathology. Diabetes causes damages to vascular endothelium, which leads 
to initial vasculopathy characterized by increased vascular permeability [53]. Along with loss of 
pericytes, this causes hemodynamics and autoregulation derangements [53, 63].
In the early stage of diabetic vasculopathy, the hyperpermeability of diabetic capillaries causes 
excessive protein to spill from the plasma into the interstitium. This leads to the offsets of 
physiological osmotic gradient, creating deficiency in fluid reabsorption on the venule end of 
the capillary bed. Edema occurs when the lymphatic system is unable to correct this imbalance 
[50]. The typical transient initial edematous course of DP suggests that optic nerve capillaries 
are susceptible to this vasculopathy. Edema compresses vessels leading to ischemia as well as 
stagnates and prolongs cellular exposure to toxic effects from free radicals and cellular waste. 
In addition, edema might also compress nerve fibers causing axoplasmic flow derangements 
[61, 62, 64]. These hypotheses would explain the reported fluroangiographic hyperfluores-
cence in DP, its relatively benign nature compared to AION, and its transient course [50].
In the later stage of DP, ischemia may result from leukostasis-derived capillary occlusion due to 
retinal leukostasis effect and thickened capillary basement membranes, which affect retinal cap-
illary endothelial function, perfusion, angiogenesis, and vascular permeability [64]. This results 
in a clinical picture resembling more like traditional AION sequelae with optic atrophy [50].
3.1.3. Clinical features
The main features of DP are painless visual loss, macular edema, disc hyperfluorescence on flu-
roangiography, and significant visual improvement after treatment [49, 54]. Differential diag-
noses include infection, inflammation, metastatic infiltration, hypertension, and papilledema 
[52, 57, 65].
3.1.4. Diagnostic studies
Certain diagnostic criteria have to be met in order to recognize diabetic papillopathy. The 
current accepted diagnostic criteria include (1) confirmed diagnosis of diabetes; (2) unilat-
eral or bilateral presence of optic disc edema; (3) normal intracranial pressure; (4) absence of 
inflammation, infiltration, or infection in the optic disc; and (5) a lack of substantial optic nerve 
dysfunction [50, 51]. Supportive examination to confirm DP includes fluorescein angiography 
(FA), orbital magnetic resonance imaging (MRI), and blood tests ranging from serum angio-
tensin-converting enzyme (ACE), antinuclear antibody (ANA), vitamin B12, folate, erythrocyte 
sedimentation rate (ESR), C reactive protein (CRP) to fluorescent treponemal antibody test [49].
3.1.5. Treatment
There is no evidence that the resolution of DP and the prevention of permanent visual loss can 
be promoted by definitive treatment. As stated before, in most cases, the edema resolves within 
a few months (average of 3.7 months) to no visual impairment [49]. Because of its self-limiting 
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nature, the most common management is serial examinations. However, due to potential 
visual sequelae noted in certain cases, more efforts have to be made to identify at-risk patients 
and effective treatment to prevent this sequela.
Although originally thought to be related to glycemic control, systemic glucose manipulation 
has not shown any benefits in DP [51]. Hence, how diabetes treatment should be titrated to 
protect visual function in DP remains uncertain [59]. Current treatment aims to reduce disc 
edema in DP, including intravitreal anti-VEGF, which has been shown to increase visual acu-
ity and decrease disc edema, and also periocular corticosteroids, which stabilizes the blood-
ocular barrier at the disc [65–69].
3.2. Neovascularization of optic disc
3.2.1. Definition
Diabetic retinopathy is often associated with neovascular proliferation due to ischemia in 
the retina and release of angiogenic factors. These conditions cause neovascularization of the 
optic disc (NVD), also neovascularization elsewhere (NVE) [70, 71]. Patients with NVD have 
a poor visual prognosis due to high incidence of complication, such as vitreous hemorrhage, 
fibrous proliferation, and traction retinal detachment. NVD occurring in DR can be accom-
panied by NVE and NVI (neovascularization of the iris), which later on may develop into 
neovascular glaucoma (NVG), which is an optic neuropathy defined by changes in the optic 
nerve and associated with visual field defects and elevated intraocular pressure [70]. Recent 
studies have shown that PDR is the leading cause of neovascular glaucoma [72].
3.2.2. Pathophysiology
In DR, capillary occlusion and reduced perfusion in retina provoke cascade events related to 
hypoxia and lead to angiogenesis. Normally, pro-angiogenic factors (VEGF and angiopoietin-2) 
and antiangiogenic factors (pigment epithelium-derived growth factor) are in equilibrium [71]. 
Imbalance between those factors might trigger activation, proliferation, and migration of endo-
thelial cells and pericytes and lead to neovascularization [71–73]. VEGF is produced in a vari-
ety of neuroretinal cells and plays a major part in promoting intraocular neovascularization. 
Inflammatory cytokines interleukin-6 (IL-6) is also correlated with the degree of neovascular-
ization patients. Other potential pro-angiogenic factors include basic fibroblast growth factor 
(bFGF), transforming growth factor-beta 1 and -beta 2, nitric oxide, and endothelin-1 [73].
The new vessels at the disc can bleed spontaneously or with minimal trauma. The blood spills 
into the retina and between the retina and vitreous causing vitreoretinal hemorrhage. This 
condition attracts fibroglial elements and finally resulting in separation between inner layers 
of the retina and the underlying retinal pigment epithelium, which is known as tractional 
retinal detachment [3]. NVD and NVI do not always develop into NVG, although neovas-
cularization always develops prior to intraocular pressure increase. This is primarily due to 
fibrovascular membrane that develops on the iris and iridocorneal angle, which later causes 
anterior synechiae, angle closure, and intraocular pressure elevation [49, 74].
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3.2.3. Clinical features
In early stages of neovascularization, patients may be asymptomatic or may present with 
low vision. Ocular findings can be subtle in early stage, so case history and complete ocular 
examination are important to make early diagnosis [71–73].
3.2.4. Diagnostic studies
Fundus examination might trace the new vessels of the optic disc and reveal glaucomatous 
optic nerve damage [73–75]. In fluorescein angiography (FA), leakage from damaged vessels 
could be detected before development of visible neovascularization. Even though FA can aid 
early detection, the test is not always available [73, 76]. Using OCT angiography (OCTA), neo-
vascularization around the optic disc at the level of the vitreous cavity might be observed in 
a faster and safer way [75]. Electroretinography and retinal angiography can be necessary to 
determine the origin of neovascularization in the retina. Meanwhile, gonioscopy is a low-cost 
and fast test, which can reveal NVI [73, 76].
3.2.5. Treatment
Early diagnosis will enable early treatment and prevent blindness due to optic nerve neo-
vascularization. Tight glycemic control is also important [75]. Medical intervention to pre-
vent further visual loss related to NVG is associated with lowering the IOP levels using 
topical β-adrenergic antagonists, α-2 agonists, and carbonic anhydrase inhibitors. Topical 
corticosteroid can also be used to reduce inflammation [73]. The main treatment for prevent-
ing NVD and NVE in DR is laser photocoagulation. Panretinal photocoagulation laser ther-
apy in early stages is beneficial by inhibiting and reversing neovascularization [74]. Use of 
anti-VEGF, cyclophotocoagulation, cryotherapy, and surgery are among other therapeutic 
options.
3.3. Optic nerve atrophy
3.3.1. Definition
Optic nerve atrophy is the end result of any disease that causes optic nerve damage anywhere 
along the path from the retina to the lateral geniculate. Degeneration of axon will manifest as 
changes in color and structure of the optic disc. It is associated with variable degrees of visual 
dysfunction, including congenital, vascular, metabolic, inflammatory condition, trauma, and 
neoplasm [77, 78].
3.3.2. Pathophysiology
Optic nerve atrophy could result from many processes related to DM and DR. Such pro-
cesses include neurodegeneration, oxidative stress, and ischemia. It may also develop as a 
result of optic nerve abnormalities mentioned above. Further study should be carried out to 
distinguish whether optic nerve atrophy occurs as a result of DR or complications of laser 
photocoagulation [10, 24, 36].
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3.3.3. Clinical features
The main symptom of optic atrophy is vision loss. In optic nerve atrophy, axon loss and myelin 
shrinkage will show the pallor-appearing disc, widening of the optic cup, and decreased 
Kestenbaum index (less than 6) [78].
3.3.4. Diagnostic studies
Optic nerve atrophy is easy to diagnose, but finding the etiology is challenging. Further 
diagnostic test is necessary to identify the etiology of optic atrophy. Imaging study, such as 
ultrasonography, CT, and MRI, is used depending on the disease process. Other diagnostic 
tests are visual acuity testing, color vision testing, contrast sensitivity test, visual field testing, 
electroretinography, optical coherence tomography, and visual evoked response [78].
3.3.5. Treatment
No proven treatment is able to return the function of atrophic optic nerve. Experts believe that 
treatment initiated before the development of optic nerve atrophy can be very useful to save 
the remaining function. The goal of primary intervention is to prevent axon degeneration by 
finding and treating the cause of optic atrophy. In diabetic patients, tight glycemic control 
and early detection of DR are very important. If the main problem is found and well-treated, 
further damage can be prevented [78].
4. Diagnostic approach for detecting optic nerve changes in diabetic 
retinopathy
Various examination methods have been used to detect functional and structural optic nerve 
changes in patients with diabetic retinopathy.
4.1. Visual functional test
4.1.1. Visual acuity
As has been known, neurodegeneration is a progressive loss of structure and function of 
neurons. The quality of visual acuity (VA) depends on the normal condition of visual path-
way. Visual acuity test is the standard test of visual function. There are two commonly used 
tools for evaluating VA, including the Snellen VA chart and the Early Treatment Diabetic 
Retinopathy Study (ETDRS) VA chart. The Snellen VA chart is a frequently used chart for mea-
suring VA. This consists of different type, size, and number of letters in each row. In contrast, 
ETDRS-VA chart has an equal number of characters per row with relatively uniform legibility. 
Some studies agree that ETDRS-VA chart has more advantages over the Snellen VA chart. 
Moreover, besides VA tests, some experts suggested that psychophysical tests, such as visual 
field and contrast sensitivity test, should also be evaluated in DR patients with optic nerve 
complication. They found that those examinations were more sensitive than VA test only [13].
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4.1.2. Contrast sensitivity
Contrast sensitivity is a test of the inner retina, with different spatial frequencies in specific neu-
ral pathways [13]. There is no algorithm to define the pattern of contrast sensitivity alteration in 
the early stage of DR. Adachi, Jochim, and Renner. observed reduced contrast sensitivity only 
at single low spatial frequency in cases of non–insulin-dependent diabetes mellitus without DR 
[79–81]. Meanwhile, Joltikov et al. and Safi et al reported decline in contrast sensitivity at all spa-
tial frequencies early in the course of diabetic retinal sensory neuropathy [14, 82]. Joltikov et al. 
suggested that contrast sensitivity might be the most sensitive test for detection of subtle func-
tional impairment in diabetic patients with or without retinopathy. In addition, contrast sensitiv-
ity test is more practical than electroretinography [13]. However, longitudinal study showed that 
reduced contrast sensitivity in the earlier stage of the disease might be reversible [82].
4.1.3. Visual fields
Another visual function affected by neurodegeneration is visual fields. A common test for 
evaluating the visual field in diabetic retinopathy is perimetry. Various perimetry methods 
have been applied including white-on-white standard automated perimetry (SAP), frequency 
doubling technology perimetry (FDP), short-wavelength automated perimetry (SWAP), and 
rarebit perimetry (RBP) [83, 84]. Bengtsson et al. suggested that SAP and SWAP are more 
sensitive to neuroretinal impairment than ETDRS-VA chart [85]. Safi et al. reported that by 
using microperimetry, it might detect a reduction of foveal sensitivity in diabetic patients 
with preclinical stage of DR [82].
4.1.4. Color vision test
Many color vision tests have been assessed in diabetic patients with and without retinopathy 
diabetes, including Lanthony desaturated D-15, Farnsworth-Munsell 100-Hue, and chromatog-
raphy tests. However, studies recommended that Farnsworth-Munsell 100-hue test has higher 
sensitivity than the other tests. This test has been recommended as a screening test for DR 
patients [82].
4.1.5. Visual evoked potential
Visual evoked potential (VEP) is a noninvasive test that evaluates the visual pathways by 
recording the electric signal in response to a bright flash of light [86, 87]. Changes of ampli-
tudes and latencies in VEP reflects impairment in ganglion cells and optic nerve [88]. Clinical 
conditions that cause a delay in VEP latencies include papillitis, neuritis, toxic optic neuropa-
thies, multiple sclerosis, glaucoma, and conditions affecting conducting media [89].
Khatoon observed that the pattern of VEP responses may provide early diagnosis of optic 
nerve involvement in DR and define the prognosis [88]. Onset of diabetes blood glucose 
control might affect the result of VEP [89]. In diabetic patients, VEP amplitude was reduced 
progressively with an increase of latency as the years pass [87]. Farisa et al. showed that 
P100 latency was prolonged among diabetic patients compared to nondiabetic subjects [88]. 
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Progressive delay in VEP latency reflects damage of ganglion cell, even before the first oph-
thalmoscopically noticeable signs arise. VEP should be done as a screening tool for detecting 
optic nerve involvement in DR. Thus, early and proper management can be done to prevent 
further ocular damage [88].
4.2. Structural test
4.2.1. Fundus photography
Fundus photography is a noninvasive examination for documenting clinical signs and moni-
toring the progression or improvement of retinal diseases over time. One of the purposes of 
fundus photography is screening DR in diabetic patients. This method is useful for illustrat-
ing normal and abnormal morphology of the retina [90, 91]. Some signs of neurodegenera-
tion in DR patients could be screened by fundus photography, including papilledema and 
macular edema. However, the result of fundus photography is a two-dimensional image; 
thus, it is difficult to accurately assess the detailed morphology of the retina leading to a high 
false-positive rate. In addition, in the condition of vitreous hemorrhage or low-quality image, 
some part of the retina could not be evaluated [10, 48].
4.2.2. Fundus fluorescein angiography
Fundus fluorescein angiography (FFA) is an invaluable imaging method demonstrating an 
interaction of fluorescent within the anatomic structure of ocular fundus. FFA is the gold 
standard in evaluating retinal vascularization. FFA has early and late phase. Early phase 
demonstrates following the injection until complete filling of retinal arteries, arterioles, and 
capillaries, while the late phase demonstrates filling of veins until gradual elimination of the 
fluorescent from the retinal vasculature. Hypofluorescence occurs due to a vascular filling 
defect or a secondary condition of a blocking effect, while hyperfluorescence may occur due 
to fluorescein leakage, staining, or pooling [10, 24, 36].
4.2.3. Optical coherence tomography
Optical coherence tomography (OCT) is a high-resolution imaging modality to measure reti-
nal morphology, including vitreoretinal interface, neurosensory retina, and subretinal space 
[48]. We can measure the retinal layer thickness and segmentation [92, 93]. OCT provides an 
accurate assessment with low specificity value [48]. OCT is divided into two types: spectral 
domain (SD) and time domain (TD) [2]. TD-OCT is mostly used in neuro-ophthalmology to 
measure peripapillary retinal nerve fiber layer (RNFL) thickness. Peripapillary RNFL thick-
ness increases in disc edema and decreases in optic nerve atrophy [94]. The results of OCT can 
be used as a guide for making therapeutic decision.
4.2.4. Optical coherence tomography angiography
Optical coherence tomography angiography (OCT-A) is a three-dimensional noninvasive cho-
rioretinal vascular imaging to observe the microvascular structures of new vessels, including 
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NVD and NVE [95]. OCT-A can analyze blood flow in the vessels without dye injections. In 
FFA, it sometimes showed artifacts due to dye leakage effect. OCT-A is superior to FFA in 
determining the number, course, size, and extension of NVD [96].
5. Conclusion
Changes in the optic nervous system may start prior to classic clinical manifestation of 
DR. The development of an integrated multimodal approach for detecting optic nerve 
involvement in DR is important for early diagnosis in preclinical stage DR and reducing 
diabetic complications.
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